Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

NVS Novartis AG

107,00

-0,22 (-0,21%)

20 Jul 2024 - Geschlossen

Verzögert um 15 Minuten

Why Ophthotech Corporation's Shares Soared in October

http://www.fool.com/investing/general/2015/11/17/why-ophthotech-corporations-shares-soared-in-octob.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub

Novartis (NYSE:NVS)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

Click Here for more Novartis Charts.

Novartis (NYSE:NVS)
Historical Stock Chart
Von Jul 2023 bis Jul 2024

Click Here for more Novartis Charts.

News

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Donnerstag 18 Juli 2024 (3 Tage vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 18 Juli 2024 (4 Tage vor) • Edgar (US Regulatory)

TSMC Net Profit Hits $7.6B; Nokia Sees 32% Decline in Operating Profit; Novartis Boosts Outlook After Profit Surge
Donnerstag 18 Juli 2024 (4 Tage vor) • IH Market News

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Donnerstag 11 Juli 2024 (1 Woche vor) • Edgar (US Regulatory)

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Montag 17 Juni 2024 (1 Monat vor) • Edgar (US Regulatory)

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
Samstag 25 Mai 2024 (2 Monate vor) • PR Newswire (US)

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Samstag 25 Mai 2024 (2 Monate vor) • PR Newswire (US)

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Freitag 24 Mai 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 22 Mai 2024 (2 Monate vor) • Edgar (US Regulatory)

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
Dienstag 7 Mai 2024 (2 Monate vor) • GlobeNewswire Inc.

Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News
Dienstag 23 April 2024 (3 Monate vor) • IH Market News

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Montag 15 April 2024 (3 Monate vor) • PR Newswire (US)

Weitere News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen